Provided by Tiger Trade Technology Pte. Ltd.

Immuneering Corp

5.16
+0.02000.39%
Post-market: 5.12-0.0390-0.76%19:57 EDT
Volume:650.99K
Turnover:3.34M
Market Cap:333.18M
PE:-4.05
High:5.25
Open:5.10
Low:5.03
Close:5.14
52wk High:10.08
52wk Low:1.29
Shares:64.57M
Float Shares:54.41M
Volume Ratio:1.10
T/O Rate:1.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2729
EPS(LYR):-1.2729
ROE:-43.12%
ROA:-26.07%
PB:1.52
PE(LYR):-4.05

Loading ...

Analysts Are Bullish on Top Healthcare Stocks: Immuneering (IMRX), Galectin Therapeutics (GALT)

TIPRANKS
·
Yesterday

Immuneering posts smaller-than-expected Q1 net loss on lower R&D spend

Reuters
·
May 15

Immuneering Q1 FY26 net loss narrows to $13.5 million

Reuters
·
May 15

Immuneering Q1 EPS $(0.21) Beats $(0.26) Estimate

Benzinga
·
May 15

Immuneering Corp - Ends Q1 2026 With $198.6 Mln in Cash and Securities; Runway Into 2029

THOMSON REUTERS
·
May 15

Immuneering Corporation Q1 Net Income USD -13.5 Million VS. Ibes Estimate USD -17.3 Million

THOMSON REUTERS
·
May 15

Press Release: Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

Dow Jones
·
May 15

Immuneering’s Phase 3 Pancreatic Cancer Trial Puts Atebimetinib in the Spotlight for IMRX Investors

TIPRANKS
·
May 08

Immuneering announces updated data from Phase 2a trial for atebimetinib

TIPRANKS
·
Apr 22

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

GlobeNewswire
·
Apr 22

Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and McKesson (MCK)

TIPRANKS
·
Apr 21

Immuneering announces annual shareholder meeting webcast

Reuters
·
Apr 21

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

GlobeNewswire
·
Apr 20

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Immuneering (IMRX) and Maze Therapeutics, Inc. (MAZE)

TIPRANKS
·
Apr 14

Immuneering CEO to join Needham Virtual Healthcare Conference fireside chat

Reuters
·
Apr 07

Immuneering to present atebimetinib ctDNA analysis at AACR Annual Meeting

Reuters
·
Mar 18

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival

GlobeNewswire
·
Mar 18

Mizuho Securities Sticks to Their Buy Rating for Immuneering (IMRX)

TIPRANKS
·
Mar 12

Immuneering price target lowered to $12 from $13 at Piper Sandler

TIPRANKS
·
Mar 09

Immuneering Price Target Maintained With a $11.00/Share by Needham

Dow Jones
·
Mar 09